Changes in regulation surrounding marijuana have sprouted a robust medical cannabis market showing no signs of slowing down globally. Currently, the U.S. dominates the cannabis market where the majority of States started adopting the new trend for cannabis treatment in 2012. Australia has been late to the game; we only began easing laws in early
Read MoreWhen you think of cannabis treatment, the first compounds that come to mind are THC (tetrahydrocannabinol) and CBD (cannabidiol). With both research and development excelling for both, researchers have discovered other less-known compounds that have significant health benefits. Medicinal cannabis drug development company Bod Australia Ltd (ASX: BOD) has successfully completed a proof of concept
Read MoreCannabis healthcare company Bod Australia (ASX: BDA) has commenced its penetration of the lucrative UK medicinal cannabis market having received its first international prescriptions for their MediCabilis™ product. With more than 7.3 million consumers of cannabis products in the UK annually, it represents a major addressable market for Bod which estimates its value to be
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.